Futura Medical plc (FUM.L) LSE
0.70
-0.028(-3.84%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
0.70
-0.028(-3.84%)
Currency In GBp
Address
Surrey Technology Centre
Guildford, GU2 7YG
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 14 8368 5670
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
July 22, 2003
| Name | Title | Pay | Year Born |
| Alex Duggan | Chief Executive Officer & Executive Director | 469,554 | N/A |
| Alexander James Hanbury Duggan | Chief Executive Officer & Executive Director | 469,554 | 1970 |
| Kenneth William James | Head of R&D & Executive Director | 351,120 | 1952 |
| Angela Hildreth | Chief Operating Officer, Finance Director, Company Secretary & Executive Director | 383,887 | 1980 |
| William Duncan Potter | Chief Scientific Officer & Adviser to the Board | 0 | 1948 |
| Graham Smith | Head of Alliance Partnerships & Supply | 0 | N/A |
| Kevin Langridge | Head of Quality | 0 | N/A |
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.